200 related articles for article (PubMed ID: 28991933)
1. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
Baron HL
J Fam Pract; 2017 Oct; 66(10 Suppl):S17-S28. PubMed ID: 28991933
[TBL] [Abstract][Full Text] [Related]
2. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
Blumer I; Pettus JH; Santos Cavaiola T
Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
[TBL] [Abstract][Full Text] [Related]
3. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Edelman SV
J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
[TBL] [Abstract][Full Text] [Related]
4. Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy.
Shubrook JH
J Fam Pract; 2018 Aug; 67(8 suppl):S49-S54. PubMed ID: 30137054
[No Abstract] [Full Text] [Related]
5. Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.
Østergaard L; Frandsen CS; Dejgaard TF; Madsbad S
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):621-632. PubMed ID: 28349716
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Basal Insulin/GLP-1 Receptor Agonist Used in Combination for Type 2 Diabetes Management.
McCarty D; Olenik A; McCarty BP
J Pharm Pract; 2019 Dec; 32(6):671-678. PubMed ID: 29566586
[TBL] [Abstract][Full Text] [Related]
7. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
Vedtofte L; Knop FK; Vilsbøll T
Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
[TBL] [Abstract][Full Text] [Related]
8. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?].
Nauck M; Wilhelm B
MMW Fortschr Med; 2017 Jun; 159(Suppl 5):7-15. PubMed ID: 28643293
[TBL] [Abstract][Full Text] [Related]
9. Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials.
Vargas-Uricoechea H; Frias JP; Vargas-Sierra HD
Rev Diabet Stud; 2023 Mar; 19(1):14-27. PubMed ID: 37185053
[TBL] [Abstract][Full Text] [Related]
10. Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.
Liakopoulou P; Liakos A; Vasilakou D; Athanasiadou E; Bekiari E; Kazakos K; Tsapas A
Endocrine; 2017 Jun; 56(3):485-494. PubMed ID: 28401444
[TBL] [Abstract][Full Text] [Related]
11. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
Rendell M
Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
[TBL] [Abstract][Full Text] [Related]
12. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.
Castellana M; Cignarelli A; Brescia F; Laviola L; Giorgino F
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3082. PubMed ID: 30270567
[TBL] [Abstract][Full Text] [Related]
13. Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis.
Weng J; Tao Y; Xu Z; Zhou S; Xiao D; Zhu Z; Zheng R; Yang Y; Chen Y
J Evid Based Med; 2024 Jun; 17(2):370-376. PubMed ID: 38858300
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes.
Vedtofte L; Knop FK; Vilsbøll T
Expert Opin Drug Saf; 2017 Mar; 16(3):387-396. PubMed ID: 28150516
[TBL] [Abstract][Full Text] [Related]
15. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.
Busch RS; Kane MP
Postgrad Med; 2017 Sep; 129(7):686-697. PubMed ID: 28657399
[TBL] [Abstract][Full Text] [Related]
16. Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.
Harris S; Abrahamson MJ; Ceriello A; Charpentier G; Evans M; Lehmann R; Liebl A; Linjawi S; Holt RIG; Hosszúfalusi N; Rutten G; Vilsbøll T
Drugs; 2020 Feb; 80(2):147-165. PubMed ID: 31960258
[TBL] [Abstract][Full Text] [Related]
17. New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin.
Frias PF; Frias JP
Curr Diab Rep; 2017 Aug; 17(10):91. PubMed ID: 28822051
[TBL] [Abstract][Full Text] [Related]
18. Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?
Simpson R; King A
Expert Rev Clin Pharmacol; 2015 Mar; 8(2):179-88. PubMed ID: 25697410
[TBL] [Abstract][Full Text] [Related]
19. [Not Available].
Fischli S; Henzen C
Ther Umsch; 2017; 74(8):433-439. PubMed ID: 29461151
[No Abstract] [Full Text] [Related]
20. FDA approval of GLP-1 receptor agonist (liraglutide) for use in children.
Bacha F
Lancet Child Adolesc Health; 2019 Sep; 3(9):595-597. PubMed ID: 31345736
[No Abstract] [Full Text] [Related]
[Next] [New Search]
